entertainment -WSS

entertainment

author：comprehensive 2025-09-27 12:54:39 - browse：8

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： The science behind Janet Jackson's pregnancy at 49

leisure time

WSS

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Weight bias in eating disorder treatment complicated by new weight loss drugs

Weight bias in eating disorder treatment complicated by new weight loss drugs

Disclosing genetic information: not as worrisome as once feared

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Fatty liver disease was alleviated by Lilly’s ‘triple

Apple is now the first public company to be valued at $3 trillion

What affirmative action's end means to a medical student

Virginia high school admissions case could be legal follow

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT's guide to the next generation of CAR

Psychedelics group wrestles with new pharma identity

Vertex cell therapy lets patients with type 1 diabetes stop insulin

explore

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Paxlovid study fails to answer questions over benefit for broader groups

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Prescription digital therapeutics are key to pharma’s future

Drug cartel violence flares in western Mexico after vigilante leader's killing

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

hotspot

leisure time

hotspot

knowledge